GNRHR: A Potential Drug Target and Biomarker for Cancer (G2798)

Target Name: GNRHR

NCBI ID: G2798

GNRHR

GNRHR: A Potential Drug Target and Biomarker for Cancer

GNRHR (Gastrin Receptor-Hepatitis Receptor) is a protein that is expressed in the liver and has been shown to play a role in the development and progression of various diseases, including liver cancer. It is also a potential drug target (or biomarker) for the treatment of these diseases.

GNRHR is a transmembrane protein that is composed of two extracellular domains: a catalytic domain and an intracellular domain. The catalytic domain is responsible for the protein's catalytic activity, while the intracellular domain is responsible for its ability to interact with other proteins inside the cell.

GNRHR is a potent regulator of cell growth and metabolism. It has been shown to play a role in the regulation of apoptosis (programmed cell death), cell cycle progression, and metabolism. GNRHR has also been shown to promote the growth and survival of cancer cells, which may contribute to its potential as a drug target.

One of the most promising aspects of GNRHR is its potential as a drug target is its ability to interact with the protein PDGF-BB (Platelet-derived growth factor-BB). PDGF-BB is a potent regulator of cell growth and has been shown to promote the growth and survival of various diseases, including cancer. By interacting with PDGF-BB, GNRHR may be able to regulate its activity and potentially contribute to the development of cancer.

GNRHR has also been shown to interact with the protein NF-kappa-B (nuclear factor kappa B). NF-kappa-B is a transcription factor that is involved in the regulation of various cellular processes, including inflammation and stress. By interacting with NF-kappa-B, GNRHR may be able to regulate its activity and potentially contribute to the development of diseases that are characterized by inflammation and stress.

In addition to its potential as a drug target, GNRHR is also a potential biomarker for the diagnosis and progression of various diseases. Its expression has been shown to be elevated in a variety of diseases, including cancer, and its levels have been used as a biomarker for the diagnosis of certain types of cancer.

GNRHR is also a potential target for small molecules, such as drugs that can modulate its activity. For example, GNRHR has been shown to be sensitive to inhibitors of the tyrosine kinase activity of PDGF-BB, which suggests that small molecules that can inhibit this activity may be effective in reducing the activity of GNRHR. Similarly, GNRHR has also been shown to be sensitive to inhibitors of the NF-kappa-B pathway, which suggests that small molecules that can inhibit this pathway may also be effective in reducing the activity of GNRHR.

In conclusion, GNRHR is a protein that has been shown to play a role in the development and progression of various diseases, including liver cancer. Its expression is also a potential drug target (or biomarker) for the treatment of these diseases. GNRHR's ability to interact with PDGF-BB and NF-kappa-B suggests that it may be a useful target for small molecules that can modulate its activity. Further research is needed to fully understand the role of GNRHR in disease and to develop effective treatments.

Protein Name: Gonadotropin Releasing Hormone Receptor

Functions: Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling

The "GNRHR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNRHR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets